Kaya Elif, Siebermair Johannes, Azizy Obayda, Dobrev Dobromir, Rassaf Tienush, Wakili Reza
Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.
Institute of Pharmacology, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.
Int J Cardiol Heart Vasc. 2019 Jul 5;24:100390. doi: 10.1016/j.ijcha.2019.100390. eCollection 2019 Sep.
Surgical implantation of subcutaneous implantable cardioverter-defibrillators (S-ICD) requires preparation of a deeper and larger pocket. Infection and bleeding complications are reported, particularly in patients requiring antiplatelet therapy (APT) or being on oral anticoagulation (OAC), with rates up to 25%. The pulsed electron avalanche knife (PEAK) PlasmaBlade™ has been reported to reduce bleeding complications. The purpose of this study was to evaluate the safety and feasibility of a PEAK guided S-ICD implantation with respect to perioperative complications.
We enrolled 36 consecutive patients (75% male; mean age 52.1 ± 14.4 years) undergoing S-ICD implantation. Periprocedural safety endpoints comprised major complications including pocket hematomas, wound infections, bleeding (BARC ≥2) or events requiring interventions. Patients were divided into three groups according to management of their anticoagulation: i.) APT, n = 15 (41.7%); ii.) OAC, n = 10 patients (27.8%); iii.) none (neither OAC nor APT), n = 11 (30.6%). Mean procedure duration was 33.1 ± 13.4 min. Mean length of hospital stay was 3.3 ± 2.1 days. Overall analysis showed no differences between the 3 groups with respect to major complications, major bleeding episodes or other procedural parameters, beside a trend towards more minor hematomas in the OAC group (OAC: 22.2% vs. APT: 11.4% vs. none: 9.1%; = 0.15).
The results of our pilot study suggest that intermuscular S-ICD implantation using PEAK is safe and potentially beneficial in patients receiving OAC or APT with respect to prevention of bleeding complications. These results support the rationale for large prospective controlled trials evaluating a beneficial effect of PEAK use in S-ICD implantation procedures.
皮下植入式心律转复除颤器(S-ICD)的外科植入需要准备更深、更大的囊袋。有报道称存在感染和出血并发症,尤其是在需要抗血小板治疗(APT)或接受口服抗凝治疗(OAC)的患者中,发生率高达25%。据报道,脉冲电子雪崩刀(PEAK)PlasmaBlade™可减少出血并发症。本研究的目的是评估在围手术期并发症方面,PEAK引导下S-ICD植入的安全性和可行性。
我们纳入了36例连续接受S-ICD植入的患者(75%为男性;平均年龄52.1±14.4岁)。围手术期安全终点包括主要并发症,如囊袋血肿、伤口感染、出血(BARC≥2级)或需要干预的事件。根据抗凝管理将患者分为三组:i.)APT组,n = 15例(41.7%);ii.)OAC组,n = 10例(27.8%);iii.)无(既无OAC也无APT)组,n = 11例(30.6%)。平均手术时间为33.1±13.4分钟。平均住院时间为3.3±2.1天。总体分析显示,三组在主要并发症、主要出血事件或其他手术参数方面无差异,不过OAC组有更多轻微血肿的趋势(OAC组:22.2% vs. APT组:11.4% vs. 无组:9.1%;P = 0.15)。
我们的初步研究结果表明,对于接受OAC或APT治疗的患者,使用PEAK进行肌间S-ICD植入在预防出血并发症方面是安全的且可能有益。这些结果支持了开展大型前瞻性对照试验以评估PEAK在S-ICD植入手术中的有益效果的理论依据。